Immunic to Engage in Key Conferences in May

Immunic, Inc., a biotechnology firm focusing on small molecule therapies for chronic inflammatory and autoimmune diseases, announced its participation in key scientific and industry conferences in May. The company, listed on Nasdaq as IMUX, will present critical findings across various events.

During the Digestive Disease Week from May 3-6 in San Diego, CA, Immunic will present two studies on IMU-856, targeting SIRT6 for treating celiac disease. Scheduled on May 6, the poster sessions aim to elucidate the efficacy and gut epithelial influence on IMU-856's pharmacokinetics.

At the Clinical Trial Supply Forum from May 13-15 in Brussels, challenges encountered in the MENA supply chain will be highlighted by Immunic's Head of Clinical Trial Supply, Kimi Oanh Le, through a case study.

The Consortium of Multiple Sclerosis Centers Annual Meeting from May 28-31 in Phoenix, AZ, will feature Immunic's preclinical data on neuroprotective effects of vidofludimus calcium (IMU-838) for multiple sclerosis, presented on May 29.